eligibility_summary
Adults 18–75 with IMWG‑defined, measurable MM, relapsed/refractory after ≥3 lines (PI, IMiD, anti‑CD38), last therapy failed or progressed ≤60 d, ECOG 1–2, recovered, adequate organs, apheresis eligible. Key exclusions: CNS disease, other plasma‑cell disorders, malignancy <3 y, active HBV/HCV/HIV/CMV/EBV, severe comorbidity/allergy, recent anticancer therapy/immunosuppression/major surgery/live vaccine, psychiatric illness/substance abuse, pregnancy/breastfeeding or planning pregnancy ≤2 y.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT05998928 (Phase 2, single-arm) in relapsed/refractory multiple myeloma after ≥3 prior lines. Interventions/mechanisms: 1) BCMA–GPRC5D CAR-T cells: autologous, gene‑modified T‑cell therapy expressing a bispecific CAR that recognizes BCMA (TNFRSF17) and GPRC5D on myeloma cells. Binding triggers CAR CD3ζ/costimulatory signaling, T‑cell activation, and tumor cell killing. Dual targeting is intended to prevent BCMA antigen escape and improve efficacy. 2) Lymphodepletion with fludarabine (purine analog/antimetabolite) and cyclophosphamide (alkylating agent) to reduce host lymphocytes and enhance CAR-T expansion/persistence. Targets: malignant plasma cells expressing BCMA and/or GPRC5D, BCMA pathway central to plasma cell survival, GPRC5D is highly expressed on MM with limited normal expression (mainly hair follicles).